Source:http://linkedlifedata.com/resource/pubmed/id/17889357
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
10
|
| pubmed:dateCreated |
2007-9-24
|
| pubmed:abstractText |
Hydroxychloroquine (HCQ) is an immunosuppressive lysosomotropic amine that has activity against graft-versus-host disease (GVHD). In a single-institution phase III trial, 95 recipients of allogeneic peripheral blood stem cell (PBSC) transplantation were randomized to receive, in a double-blind fashion, and in addition to prophylactic cyclosporine A (CSA), HCQ, or placebo starting 21 days pretransplant and continued until day +365. HCQ was very well tolerated and not associated with side effects. Overall, the incidence of acute GVHD (aGVHD) was 59% in both arms, and severe aGVHD occurred in 11% (HCQ) and 14% (placebo) (P = .76). Sixty percent and 78% of patients developed chronic GVHD (cGVHD) in the HCQ and the placebo arms, respectively (P = .15). With a median follow-up of 18 months, relapse-free and overall survivals (OS) were comparable in both groups. In summary, in this randomized trial, the addition of HCQ to single-agent CSA had no effects on aGVHD or cGVHD or survival.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Oct
|
| pubmed:issn |
1083-8791
|
| pubmed:author |
pubmed-author:AdkinsDouglasD,
pubmed-author:DevineSteven MSM,
pubmed-author:DipersioJohn FJF,
pubmed-author:FongThomasT,
pubmed-author:GoodnoughLawrence TLT,
pubmed-author:GraubertTimothyT,
pubmed-author:KhouryHanna JHJ,
pubmed-author:LopezSandraS,
pubmed-author:ShenoyShaliniS,
pubmed-author:TomassonMichaelM,
pubmed-author:TrinkausKathrynK,
pubmed-author:VijRaviR
|
| pubmed:issnType |
Print
|
| pubmed:volume |
13
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1201-6
|
| pubmed:dateRevised |
2010-11-18
|
| pubmed:meshHeading |
pubmed-meshheading:17889357-Adult,
pubmed-meshheading:17889357-Chronic Disease,
pubmed-meshheading:17889357-Disease-Free Survival,
pubmed-meshheading:17889357-Double-Blind Method,
pubmed-meshheading:17889357-Female,
pubmed-meshheading:17889357-Graft vs Host Disease,
pubmed-meshheading:17889357-Hematologic Neoplasms,
pubmed-meshheading:17889357-Humans,
pubmed-meshheading:17889357-Hydroxychloroquine,
pubmed-meshheading:17889357-Immunosuppressive Agents,
pubmed-meshheading:17889357-Kaplan-Meier Estimate,
pubmed-meshheading:17889357-Male,
pubmed-meshheading:17889357-Middle Aged,
pubmed-meshheading:17889357-Peripheral Blood Stem Cell Transplantation,
pubmed-meshheading:17889357-Transplantation, Homologous,
pubmed-meshheading:17889357-Transplantation Conditioning,
pubmed-meshheading:17889357-Treatment Outcome
|
| pubmed:year |
2007
|
| pubmed:articleTitle |
A randomized double-blind trial of hydroxychloroquine for the prevention of chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation.
|
| pubmed:affiliation |
Division of Oncology, Section of Leukemia & Bone Marrow Transplantation, Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri, USA.
|
| pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase III
|